[1] Amoozgar B, Lin S C, Han Y, et al. A role for antimetabolites in glaucoma tube surgery[J]. Current Opinion in Ophthalmology, 2016, 27(2): 164-169.
[2] Quigley H A, Broman A T. The number of people with glaucoma worldwide in 2010 and 2020[J]. Br J Ophthalmol, 2006, 90(3): 262-7.
[3] Wang X, Khan R, Coleman A. Device-modified trabeculectomy for glaucoma. The Cochrane database of systematic reviews. 2015: CD010472.
[4] Perez C I, Mellado F, Jones A, et al. Trabeculectomy Combined With Collagen Matrix Implant (Ologen)[J]. J Glaucoma, 2017, 26(1): 54-58.
[5] Cairns J E. Trabeculectomy. Preliminary report of a new method[J]. American journal of ophthalmology, 1968, 66(4): 673-679.
[6] Watson P G, Barnett F. Effectiveness of trabeculectomy in glaucoma[J]. American journal of ophthalmology, 1975, 79(5): 831-845.
[7] Jampel H D, Mcguigan L J, Dunkelberger G R, et al. Cellular proliferation after experimental glaucoma filtration surgery[J]. Archives of ophthalmology (Chicago, Ill. : 1960), 1988, 106(1): 89-94.
[8] Fontana H, Nouri-Mahdavi K, Lumba J, et al. Trabeculectomy with Mitomycin C: outcomes and risk factors for failure in phakic open-angle glaucoma[J]. Ophthalmology, 2006, 113(6): 930-936.
[9] Bindlish R, Condon G P, Schlosser J D, et al. Efficacy and safety of Mitomycin-C in primary trabeculectomy: five-year follow-up[J]. Ophthalmology, 2002, 109(7): 1336-41; discussion 1341-2.
[10] Cillino S, Zeppa L, Di Pace F, et al. E-PTFE (Gore-Tex) implant with or without low-dosage Mitomycin-C as an adjuvant in penetrating glaucoma surgery: 2 year randomized clinical trial[J]. Acta Ophthalmol, 2008, 86(3): 314-21.
[11] Allen L E, Manuchehri K, Corridan P G. The treatment of encapsulated trabeculectomy blebs in an out-patient setting using a needling technique and subconjunctival 5-fluorouracil injection[J]. Eye (London, England), 1998, 12 ( Pt 1): 119-123.
[12] Spaeth G L, Mutlukan E. The use of antimetabolites with trabeculectomy: a critical appraisal[J]. Journal of glaucoma, 2001, 10(3): 145-151.
[13] Hsu W-C, Ritch R. Biodegradable collagen matrix implant for trabeculectomy AU - Zelefsky, Joseph R[J]. Expert Review of Ophthalmology, 2008, 3(6): 613-617.
[14] Biteli L G, Prata T S. Subconjunctival bevacizumab as an adjuvant in first-time filtration surgery for patients with primary glaucomas[J]. International ophthalmology, 2013, 33(6): 741-746.
[15] Simsek T, Cankaya A B, Elgin U. Comparison of needle revision with subconjunctival bevacizumab and 5-fluorouracil injection of failed trabeculectomy blebs[J]. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2012, 28(5): 542-546.
[16] Vahedian Z, Mafi M, Fakhraie G, et al. Short-term Results of Trabeculectomy Using Adjunctive Intracameral Bevacizumab Versus Mitomycin C: A Randomized Controlled Trial[J]. Journal of glaucoma, 2017, 26(9): 829-834.
[17] Kaushik J, Parihar J K, Jain V K, et al. Efficacy of Bevacizumab Compared to Mitomycin C Modulated Trabeculectomy in Primary Open Angle Glaucoma: A One-Year Prospective Randomized Controlled Study[J]. Curr Eye Res, 2017, 42(2): 217-224.
[18] Chen H-J, Lin C, Lee C-H, et al. Efficacy and Safety of Bevacizumab Combined with Mitomycin C or 5-Fluorouracil in Primary Trabeculectomy: A Meta-Analysis of Randomized Clinical Trials[J]. Ophthalmic research, 2018, 59(3): 155-163.
[19] Narayanaswamy A, Perera S A, Htoon H M, et al. Efficacy and safety of collagen matrix implants in phacotrabeculectomy and comparison with Mitomycin C augmented phacotrabeculectomy at 1 year[J]. Clin Exp Ophthalmol, 2013, 41(6): 552-60.
[20] Papaconstantinou D, Georgalas I, Karmiris E, et al. Trabeculectomy with Ologen versus trabeculectomy for the treatment of glaucoma: a pilot study[J]. Acta Ophthalmologica, 2010, 88(1): 80-85.
[21] Hsu W-C, Ritch R, Krupin T, et al. Tissue bioengineering for surgical bleb defects: an animal study[J]. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2008, 246(5): 709-717.
[22] Yuan F, Li L, Chen X, et al. Biodegradable 3D-Porous Collagen Matrix (Ologen) Compared with Mitomycin C for Treatment of Primary Open-Angle Glaucoma: Results at 5 Years[J]. J Ophthalmol, 2015, 2015: 637537.
[23] Cillino S, Di Pace F, Cillino G, et al. Biodegradable collagen matrix implant vs Mitomycin-C as an adjuvant in trabeculectomy: a 24-month, randomized clinical trial[J]. Eye (Lond), 2011, 25(12): 1598-606.
[24] Singab A a S, Mohammed O A, Saleem M I H, et al. A Comparative Study: The Use of Collagen Implant versus Mitomycin-C in Combined Trabeculotomy and Trabeculectomy for Treatment of Primary Congenital Glaucoma[J]. J Ophthalmol, 2017, 2017: 9241459.
[25] Eldaly Z, Maasoud A, Saad M, et al. Comparison between Ologen implant and different concentrations of Mitomycin C as an adjuvant to trabeculectomy surgery[J]. Oman Journal of Ophthalmology, 2017, 10(3): 184.
[26] Sarker B K D, Abdullahi S M, Hassan Z, et al. Outcome of trabeculectomy with Ologen versus Mitomycin C: A comparative prospective study in Bangladesh[J]. European Journal of Ophthalmology, 2018: 112067211877184.
[27] Marey H M, Mandour S S, Ellakwa A F. Subscleral trabeculectomy with Mitomycin-C versus Ologen for treatment of glaucoma[J]. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2013, 29(3): 330-334.
[28] Mohamed T H, Salman A G, Elshinawy R F. Trabeculectomy with Ologen implant versus Mitomycin C in congenital glaucoma secondary to Sturge Weber Syndrome. International journal of ophthalmology. 2018: 251-255.
[29] El-Sayyad F, El-Saied H M A, Abdelhakim M. Trabeculectomy with Ologen versus Mitomycin C in Juvenile Open-Angle Glaucoma: A 1-Year Study[J]. Ophthalmic Res, 2017, 57(4): 230-238.
[30] Rosentreter A, Schild A M, Jordan J F, et al. A prospective randomised trial of trabeculectomy using Mitomycin C vs an Ologen implant in open angle glaucoma[J]. Eye (Lond), 2010, 24(9): 1449-57.
[31] Rosentreter A, Gaki S, Cursiefen C, et al. Trabeculectomy Using Mitomycin C versus an Atelocollagen Implant: Clinical Results of a Randomized Trial and Histopathologic Findings[J]. Ophthalmologica, 2014, 231(3): 133-140.
[32] Higgins J, Green S P, Cochrane C. Cochrane handbook for systematic reviews of interventions[M]. John Wiley & Sons, 2008: xxi, 649 p.
[33] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement[J]. Bmj, 2009, 339(jul21 1): b2535-b2535.
[34] Cillino S, Casuccio A, Di Pace F, et al. Biodegradable collagen matrix implant versus Mitomycin-C in trabeculectomy: five-year follow-up[J]. BMC Ophthalmol, 2016, 16: 24.
[35] Yu L, Qin H. Collagen matrix compared with Mitomycin C for treatment of primary open-angle glaucoma with trabeculectomy performed[M]. 17. 2017: 1712-1715.
[36] Tanna A P, Rademaker A W, De Moraes C G, et al. Collagen matrix vs Mitomycin-C in trabeculectomy and combined phacoemulsification and trabeculectomy: a randomized controlled trial[J]. BMC Ophthalmol, 2016, 16(1): 217.
[37] Maheshwari D, Ramakrishnan, Gupta A. Comparative study of MMC augmented trabeculectomy vs an Ologen implant in open angle glaucoma[J]. Glaucoma Free Papers, 2012.
[38] Senthil S, Rao H L, Babu J G, et al. Comparison of outcomes of trabeculectomy with Mitomycin C vs. Ologen implant in primary glaucoma[J]. Indian J Ophthalmol, 2013, 61(7): 338-42.
[39] Nilforushan N, Yadegari M, Hodjat P. Comparison of the Success Rate of Trabeculectomy with OculusGen versus Trabeculectomy with Mitomycin C[J]. IRJO, 2011, 23(4): 3-12.
[40] Mitra A, R R K, Pmt M a K, et al. To Compare the Outcome, Complications and Management of Complications of Trabeculectomy with Ologen Implant Versus Trabeculectomy with MMC[J]. Glaucoma Free Papers, 2012.
[41] Addicks E M, Quigley H A, Green W R, et al. Histologic characteristics of filtering blebs in glaucomatous eyes[J]. Archives of ophthalmology (Chicago, Ill. : 1960), 1983, 101(5): 795-798.
[42] Hitchings R A, Grierson I. Clinico pathological correlation in eyes with failed fistulizing surgery[J]. Transactions of the ophthalmological societies of the United Kingdom, 1983, 103 ( Pt 1): 84-88.
[43] Tanito M, Okada A, Mori Y, et al. Subconjunctival implantation of Ologen Collagen Matrix to treat ocular hypotony after filtration glaucoma surgery[J]. Eye (Lond), 2017, 31(10): 1475-1479.
[44] Dietlein T S, Lappas A, Rosentreter A. Secondary subconjunctival implantation of a biodegradable collagen-glycosaminoglycan matrix to treat ocular hypotony following trabeculectomy with Mitomycin C[J]. The British journal of ophthalmology, 2013, 97(8): 985-988.
[45] Elhefney E M, Al-Sharkawy H T, Kishk H M, et al. Safety and efficacy of collagen matrix implantation in infantile glaucoma[J]. European journal of ophthalmology, 2017, 27(3): 289-294.